Tad Thomas - Vera Therapeutics Sr Manufacturing
| VERA Stock | USD 43.44 2.22 4.86% |
Insider
Tad Thomas is Sr Manufacturing of Vera Therapeutics
| Age | 61 |
| Address | 8000 Marina Boulevard, Brisbane, CA, United States, 94005 |
| Phone | 650 770 0077 |
| Web | https://veratx.com |
Vera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4605) %, meaning that it created substantial loss on money invested by shareholders. Vera Therapeutics' management efficiency ratios could be used to measure how well Vera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of September 27, 2024, Return On Tangible Assets is expected to decline to -0.57. In addition to that, Return On Capital Employed is expected to decline to -0.7. At present, Vera Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 10.5 M, whereas Total Assets are forecasted to decline to about 99.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Kimberly MD | Zentalis Pharmaceuticals Llc | 55 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Shanna Peek | Sana Biotechnology | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| Sunil MD | Sana Biotechnology | 54 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Carrie MD | Zentalis Pharmaceuticals Llc | 54 | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| MD FACP | AN2 Therapeutics | 76 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.25 |
Vera Therapeutics Leadership Team
Elected by the shareholders, the Vera Therapeutics' board of directors comprises two types of representatives: Vera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vera. The board's role is to monitor Vera Therapeutics' management team and ensure that shareholders' interests are well served. Vera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tad Thomas, Sr Manufacturing | ||
| Lauren MBA, Chief Officer | ||
| Marshall MD, President, Founder | ||
| Julien JD, Senior Legal | ||
| Joanne Curley, Chief Officer | ||
| Kerry MD, Senior Affairs | ||
| Joseph MBA, Senior Officer | ||
| Robert MD, Chief Officer | ||
| Sean MBA, Chief Officer | ||
| Neeraj MBA, Senior Manufacturing | ||
| Celia MD, Chief Officer | ||
| Kelly Rauber, Senior Resources | ||
| William Turner, Chief Officer | ||
| Tom Doan, Senior Operations | ||
| David MBA, Chief Officer | ||
| Lauren Frenz, Chief Officer |
Vera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 2.13 B | ||||
| Shares Outstanding | 54.83 M | ||||
| Shares Owned By Insiders | 7.85 % | ||||
| Shares Owned By Institutions | 92.15 % | ||||
| Number Of Shares Shorted | 6.46 M | ||||
| Price To Earning | 17.01 X | ||||
| Price To Book | 7.51 X | ||||
| EBITDA | (103.87 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| MSFT | Microsoft | |
| MSFT | Microsoft |
Additional Information and Resources on Investing in Vera Stock
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Return On Assets (0.25) | Return On Equity (0.46) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.